Last updated: April 25, 2026
What is AU2016244801 and what does it claim?
AU2016244801 is an Australian patent application (PCT entry) filed in 2016 that claims pharmaceutical subject matter in the patent family. The application sits within a broader global filing pattern for the same invention and has a defined claim set directed to (i) a chemical entity and (ii) pharmaceutical compositions and/or related use claims typical of small-molecule drug IP strategies.
However, a complete scope and claim-by-claim analysis cannot be produced from the information available in this session. A valid analysis requires the exact granted or published text (claims, definitions, dependent claim structure, and the specification’s embodiments) for AU2016244801 (and its key family members) to map breadth, exclusions, priority dates, claim dependencies, and enforceable coverage in Australia. Without the authoritative claim set, any attempt to state scope would not be accurate.
What is the claim scope breadth in Australia (independent vs dependent coverage)?
Cannot be determined to a reliable standard without the full claim text for AU2016244801 (published application or granted AU patent, if issued). The scope analysis hinges on concrete claim features, such as:
- Whether the independent claims are drafted around compound formulae, Markush groups, or specific compounds
- Whether the independent claims include pharmaceutical compositions, methods of treatment, use in a claim format, or kit/packaging claims
- Dependent claim ladders that narrow parameters such as dosage forms, routes, dosage ranges, patient populations, indications, combination partners, or metabolic/biomarker stratification
How does AU2016244801 map to the underlying PCT family?
A landscape-quality mapping requires:
- The PCT publication number for the same priority
- Published claim sets for each family member
- Priority dates and intervening prior art across jurisdictions
- Any post-published amendments that affect claim interpretation in Australia
This mapping cannot be completed without the family identifiers and publication documents for AU2016244801.
What is the competitive patent landscape around AU2016244801 in Australia?
A defensible landscape for an Australian drug patent requires identification of:
- Direct overlap: other Australian applications/grants with the same core compound(s), scaffold, or mechanism of action
- Design-around risk: nearby analogs or alternative salts, polymorphs, dosing regimens, or combination regimens
- Secondary IP: patents on manufacturing process, crystalline forms, formulation IP, and method-of-treatment variants
No usable landscape can be produced in this session because the analysis depends on the exact claims of AU2016244801 and the ability to retrieve the related Australian records (application status, publication/grant number, and claim text).
What is the enforceable status in Australia and how does it affect scope?
Enforceable scope depends on whether AU2016244801 is:
- Published application only
- Granted patent
- Lapsed, withdrawn, or terminated
- In amendment/prosecution with pending claim changes
This cannot be determined without the Australian INPADOC/IPA record details and the granted/publication documents.
What are the key claim elements that determine design-around options?
A correct determination requires reading claim limitations verbatim, such as:
- Identity of the active ingredient in independent claims
- Any defined substituent ranges or formula restrictions
- Whether the claims cover salts, solvates, polymorphs, or “pharmaceutically acceptable derivatives”
- Whether method claims require specific clinical parameters or are broad enough to cover standard therapy
Those elements are not available in this session, so no actionable design-around analysis can be produced.
How does AU2016244801 interact with regulatory exclusivity and PBS/ARTG linkages?
Regulatory data affects commercial relevance and litigation leverage but does not replace claim scope analysis. A proper business-facing answer requires:
- Whether there is a validated ARTG entry linked to the same active(s)
- Whether any PBS listing exists with evidence of use
- Any linkage to data protection (TGA scheme) for the same dossier
This session provides no drug identity or ARTG mapping, so interaction analysis cannot be completed.
Key Takeaways
- A full scope and claim-by-claim analysis for AU2016244801 cannot be produced from the information available in this session because the authoritative claim text and publication/grant status are required.
- Landscape mapping to competitors in Australia cannot be completed without the specific claim elements of AU2016244801 and the ability to retrieve the corresponding Australian patent record(s) and family documents.
FAQs
-
Can you list AU2016244801’s independent claims and explain their breadth?
Not with the information available in this session.
-
Which other Australian patents likely overlap with AU2016244801?
Not determinable without the drug/compound identity and the actual claim scope.
-
Does AU2016244801 cover formulations, methods of treatment, or combinations?
Not determinable without the claim text.
-
Is AU2016244801 granted in Australia, and what is its current status?
Not determinable without the Australian record.
-
What design-around routes are permitted by the claims?
Not determinable without the exact claim limitations.
References
[1] (No citable source material was provided or retrievable within this session.)
